Clinical trialNCT03118765CompletedPhase 2Interventional

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

SponsorGlenmark Specialty S.A.Enrollment155Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Cynthia Caracta, MD FCCP
Glenmark Pharmaceuticals S.A.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Glenmark Investigational Site 23
Andalusia, Alabama, United States
Glenmark Investigational Site 12
Phoenix, Arizona, United States
Glenmark Investigational Site 14
Tempe, Arizona, United States
Glenmark Investigational Site 17
Fullerton, California, United States
Glenmark Investigational Site 19
Edgewater, Florida, United States
Glenmark Investigational Site 16
Miami, Florida, United States
Glenmark Investigational Site 24
Miami, Florida, United States
Glenmark Investigational Site 10
Miami Lakes, Florida, United States
Glenmark Investigational Site 6
Orlando, Florida, United States
Glenmark Investigational Site 20
Ormond Beach, Florida, United States
Glenmark Investigational Site 21
Vero Beach, Florida, United States
Glenmark Investigational Site 13
Winter Park, Florida, United States
Glenmark Investigational Site 18
Las Vegas, Nevada, United States
Glenmark Investigational Site 9
Charlotte, North Carolina, United States
Glenmark Investigational Site 22
Columbus, Ohio, United States
Glenmark Investigational Site 5
Columbus, Ohio, United States
Glenmark Investigational Site 8
Dublin, Ohio, United States
Glenmark Investigational Site 11
Medford, Oregon, United States
Glenmark Investigational Site 3
Easley, South Carolina, United States
Glenmark Investigational Site 2
Greenville, South Carolina, United States
Glenmark Investigational Site 4
Greenville, South Carolina, United States
Glenmark Investigational Site 1
Rock Hill, South Carolina, United States
Glenmark Investigational Site 15
Spartanburg, South Carolina, United States
Glenmark Investigational Site 7
Spartanburg, South Carolina, United States
Glenmark Investigational Site 25
Tomball, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GSP304 Inhalation SolutionGSP304 Placebo Inhalation SolutionSpiriva® Respimat® inhalation spray

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Mar 2017
Primary completion: 31 Jul 2017
Completion: 31 Jul 2017
Last update posted: 1 Aug 2019
Registered enrollment: 155
Registry id: NCT03118765

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.